ArticleRespirology case reports2026
The Eye Never Lies: When A Lesion Unveils Lung Cancer.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Eye Never Lies: When A Lesion Unveils Lung Cancer.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular manifestations rarely represent the first sign of systemic malignancy and often pose a diagnostic challenge. While choroidal metastases are more common, iris involvement is uncommon and may be underrecognized. Lung adenocarcinoma, particularly non-small cell subtypes, is a known source of ocular metastases, with iris lesions occasionally preceding systemic symptoms. We report a 70-year-old previously healthy man presenting with one month of left eye blurred vision. Initial examination revealed conjunctival injection and visual acuity of 6/20 without detectable lesions; topical dexamethasone was prescribed. Six weeks later, vision declined to finger counting, and a hypopigmented iris mass (7.0 × 5.7 mm) was identified. A brain MRI revealed a right occipital lesion, and a CECT of the thorax, abdomen, and pelvis showed a left lung mass with bilateral nodules, mediastinal lymphadenopathy, and right iliac metastasis. CT-guided biopsy confirmed stage IV lung adenocarcinoma (TTF-1 and Napsin A positive, PD-L1 TPS 80%, EGFR/ALK/ROS1 negative). Pembrolizumab was initiated; filamentous keratitis developed during therapy, and progression at three months prompted conventional chemotherapy. This case emphasizes the rarity of iris metastasis as the initial presentation of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.